Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12365659

    Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12365719

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12365693

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12358892

    Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders

    Miralogx LLC · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12359204

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12358909

    Capsazepine analogs for the treatment of cancer and other proliferative diseases

    The Board of Regents of the University of Texas System · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12357650

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12357666

    Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof

    The First Hospital of China Medical University · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12357615

    Compositions for the treatment of brain tumors

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12358968

    Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer

    Providence Health & Services—Oregon · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12350318

    Combination therapy to treat brain cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12351560

    Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12344676

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12343342

    Methods for treating soft tissue sarcoma

    Lixte Biotechnology, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12345709

    CLAUDIN18 antibodies and methods of treating cancer

    The Regents of the University of California · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12336973

    Cancer therapeutic compositions and methods targeting DNAse1L3

    Providence Health & Services—Oregon · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12336985

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12336990

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12331079

    Oncolytic virus platform to treat cancers with myxoma virus

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12329739

    Isoflavonoid compounds and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12332245

    Cancer biomarkers and methods of use thereof

    The Regents of the University of California · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12329784

    Gut microbiota and treatment of cancer

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12325691

    Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain

    The Board of Regents of the University of Texas System · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12325755

    Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

    The Regents of the University of California · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12325705

    Small molecules for the treatment of primary cancer and cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12325854

    Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

    Editas Medicine, Inc. · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. WO 2025114529

    ANTICORPS MULTISPÉCIFIQUES RECONNAISSANT L'ALBUMINE SÉRIQUE HUMAINE, TCR ET FRACTION RECONNAISSANT L'ANTIGÈNE TUMORAL

    ABLYNX NV [BE] · Granted Thu Jun 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Karyopharm Therapeutics Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12318401

    Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy

    The Regents of the University of California · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12318364

    Isoflavonoid compositions and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12311017

    Identification of immunologically protective neo-epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12310986

    Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress

    The Board of Regents of the University of Texas System · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12310965

    Treatment of cancer utilizing an identified adenosine fingerprint

    Arcus Biosciences, Inc. · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12303724

    Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

    Takeda Pharmaceutical Company Limited · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12297509

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    MIRA DX, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12291559

    Compositions and methods for treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12291502

    Topoisomerase II-alpha inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12286483

    Method of treating cancer using CD137 antibodies and PD-1 antagonists

    Compass Therapeutics LLC · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12285473

    Cancer vaccines targeting MUC16 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12280120

    Tumor-specific cleavable linkers

    Xilio Development, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12280159

    Therapeutic protein-based nanoparticles for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12281079

    Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer

    Lead Discovery Center GmbH · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12281310

    Use of trinucleotide repeat RNAs to treat cancer

    Northwestern University · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12275685

    Oligo-benzamide analogs and their use in cancer treatment

    The Board of Regents of the University of Texas System · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.